Bright Minds Biosciences files as a foreign issuer, and its SEC reports document clinical-stage biotechnology operations, capital formation and public-company governance. Form 6-K reports include interim condensed consolidated financial statements, management's discussion and analysis, executive certifications, material-event releases and exhibits incorporated by reference into Form F-3 registration statements.
The filings cover capital-structure disclosures for common shares, shelf registrations, public offerings and equity distribution arrangements, as well as clinical and regulatory updates for the company's 5-HT receptor agonist pipeline, including BMB-101. They also record operating and financial results, material agreements and shareholder voting matters tied to development-stage CNS drug programs.
Bright Minds Biosciences Inc. reports results from its annual general meeting held on March 31, 2026. A total of 7,877,637 common shares were voted, representing 80.49% of votes attached to common shares outstanding as of the record date. Votes for the six director nominees were: Ian McDonald, 99.99%; Nils Bottler, 89.76%; Jeremy Fryzuk, 97.62%; Jan Pedersen, 92.48%; David Weiner, 97.61%; and Steve Farr, 100.00%. Shareholders appointed De Visser Gray LLP, Chartered Professional Accountants, as auditor.
Bright Minds Biosciences Inc. (DRUG) said it will participate in the FPWR 2026 Research Symposium on October 7-8 and the PWS Family Conference on October 9-10 at the Marriott Philadelphia Downtown. Its BMB-101 program is being evaluated in NOVA, a randomized, double-blind, placebo-controlled Phase 2a study assessing hyperphagia, PWS-associated behaviors, safety and tolerability over a 16-week treatment period, with an optional open-label extension.
The company also entered a mutual rescission and release agreement with an officer to rescind a prior stock-option exercise for 44,500 common shares. The shares issued on exercise will be returned to treasury and cancelled, the aggregate exercise price refunded, and the options restored on their original terms, including exercise price, vesting schedule and expiry date. No other options are affected.
Bright Minds Biosciences Inc. reported a net loss of $20.4 million for the nine months ended June 30, 2026, compared with $8.1 million a year earlier, driven mainly by a sharp rise in research and development spending to $28.0 million as clinical and preclinical programs expanded. The company has no product revenue and remains dependent on external financing, but closed significant equity raises, including a January 2026 public offering, lifting cash and cash equivalents to $307.8 million and working capital to $307.7 million, which management expects to fund operations for at least the next 12 months.
The lead asset BMB‑101, a selective 5‑HT2C agonist, produced encouraging Phase 2 results in the BREAKTHROUGH study, with a 73.1% median reduction in absence seizures and 63.3% median reduction in major motor seizures in highly treatment‑resistant patients, supporting preparations for global registrational trials. The company is also advancing BMB‑101 into Prader‑Willi syndrome, progressing preclinical candidate BMB‑105, and developing 5‑HT2A and 5‑HT2A/2C agonists (BMB‑202, BMB‑201) for depression, pain and other neuro‑psychiatric indications, while maintaining a strong cash position but accepting continued dilution and high R&D outlays.
Cormorant Asset Management, LP and Bihua Chen report a significant ownership stake in Bright Minds Biosciences Inc. They report beneficial ownership of 900,000 Common Shares, representing 9.17% of the class, based on 9,812,061 Common Shares outstanding as of May 15, 2026.
The shares are held by certain Cormorant funds, with the Reporting Persons having shared voting power over 900,000 shares and shared dispositive power over 900,000 shares, and no sole voting or dispositive power. Cormorant Global Healthcare Master Fund, LP has the right to receive dividends or sale proceeds from more than 5% of the shares.
Adage Capital Management, L.P. and related parties report beneficial ownership of Bright Minds Biosciences Inc. Common Shares. Through Adage Capital Partners, L.P., they beneficially own 335,000 Common Shares, representing 3.41% of the class, based on 9,812,061 shares outstanding as of May 15, 2026.
The reporting persons have shared voting and shared dispositive power over all 335,000 shares and no sole voting or dispositive power. Adage Capital Management, L.P. is the investment manager to Adage Capital Partners, L.P., while Robert Atchinson and Phillip Gross are managing members of affiliated general partner entities. The filing states that each reporting person disclaims admission of beneficial ownership of the securities beyond what is reported.
Bright Minds Biosciences Inc. insider Ian McDonald reports beneficial ownership of 1,398,290 common shares, equal to about 13.6% of the company’s outstanding stock as of July 2, 2026. This total includes shares held directly and reflects his sole voting and dispositive power over them.
The amendment also describes earlier ownership levels, when the same 1,396,665-share position represented 19.0%, 17.9% and 13.8% of outstanding shares at different dates as the company’s share count changed. McDonald remains President, Chief Executive Officer and Director and may increase or decrease his holdings depending on market and business conditions.
Bright Minds Biosciences Inc. is calling its annual general meeting of shareholders for March 31, 2026 in Vancouver at 10:00 a.m. Pacific Time. Shareholders will receive the audited consolidated financial statements for the year ended September 30, 2025, vote on electing six directors (including one new nominee, Steve Farr), and appoint De Visser Gray LLP as auditor with remuneration set by the board. The company is using Canadian notice-and-access rules, so proxy materials and the management information circular are available online, with paper copies on request. Shareholders of record on February 10, 2026, when 9,787,161 common shares were outstanding, may vote by internet, phone, mail or in person, with a proxy deadline of March 27, 2026.
Bright Minds Biosciences Inc. has filed details for its upcoming Annual General Meeting of security holders. The record date for notice, voting, and beneficial ownership determination is set for February 10, 2026, meaning holders of common shares on that date will be entitled to participate.
The Annual General Meeting is scheduled for March 31, 2026 in Vancouver. The company will use notice-and-access for both registered and beneficial holders, and it will not send proxy materials directly to NOBOs or pay for delivery to OBOs, indicating that intermediaries will handle most material distribution.
Bright Minds Biosciences Inc. reported that it will present at the Jefferies Global Healthcare Conference on June 3, 2026 at 4:20 p.m. EDT, with a live and archived webcast available through its investor website for 30 days.
The Company also granted stock options to directors, officers and consultants to purchase an aggregate of 109,000 common shares under its share option plan. The options are exercisable at US$83.40 per share for five years and vest in four equal annual installments of 25%, starting on the first anniversary of the grant date.